SLF2 and diffuse large B-cell lymphoma: To investigate an adverse association of SLF2 expression and susceptibility to cyclophosphamide, a standard drug for DLBCL first‐line therapy, we treated human SU‐DHL‐5 DLBCL cells lacking SLF2 with increasing doses of mafosfamide (MAF, active form of cyclophosphamide).